KRAS and neoplasm: ,18,19,29,30 Therefore, we conducted a genomic analysis on 37 of 57 patients (65%) with evaluable baseline tumor biopsies who received 900 μg/kg of mitazalimab revealing KRAS as the most frequently mutated oncogene (89%) and TP53 as the most commonly mutated tumor suppressor gene (35%) (Figure 2A; Figure S2).